KRAS P.G12C
Clinical trials for KRAS P.G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS P.G12C trials appear
Sign up with your email to follow new studies for KRAS P.G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets 'Undruggable' lung cancer mutation in older and frail patients
Disease control OngoingThis trial is testing a pill called adagrasib for people with advanced lung cancer that has a specific genetic change called KRAS G12C. It focuses on patients who are 70 or older or who are in poorer health, groups often left out of other studies. The main goal is to see if the p…
Matched conditions: KRAS P.G12C
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Scientists hunt clues in blood to outsmart cancer drug resistance
Knowledge-focused OngoingThis study aims to learn why cancers with a specific KRAS mutation become resistant to targeted drugs. Up to 500 adults in the US whose cancer has progressed on these drugs will provide a blood sample or share their existing test results. Researchers will analyze these samples to…
Matched conditions: KRAS P.G12C
Sponsor: Addario Lung Cancer Medical Institute • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:16 UTC